Skip to main content
SpringerLink
Log in

Prophylaxis with turoctocog alfa pegol in severe haemophilia A: fewer bleeds, lower costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Novo Nordisk A/S.

Reference

  • Benson G, et al. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. ClinicoEconomics and Outcomes Research : 18 Jan 2021. Available from: URL: https://doi.org/10.2147/CEOR.S280574

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prophylaxis with turoctocog alfa pegol in severe haemophilia A: fewer bleeds, lower costs. PharmacoEcon Outcomes News 871, 31 (2021). https://doi.org/10.1007/s40274-021-7469-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7469-6

Search

Navigation